| Budget Amount *help |
¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2011: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2010: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Research Abstract |
In the present study, we have studied the effects and mechanisms of nestin-targeting therapy in pancreatic cancers. Inhibition of nestin in pancreatic cancer cell lines suppressed cell migration, invasion, sphere-forming ability and liver metastasis. The inhibitory effects of nestin were involved in the expression levels of F-actin, E-cadherin and transcription factor 4. We found that nestin expression was regulated by the methylation of the nestin gene and by the activation of cell signaling pathway proteins such as PKR and AKT. Tail vein injections of siRNA-targeting nestin into immunodeficient mice in which human pancreatic cancer had been transplanted suppressed both primary and metastatic tumor formation. Nestin is considered a promising target for pancreatic cancers, and further studies are needed to develop nestin-targeting therapy for pancreatic cancer.
|
